NEW YORK (GenomeWeb News) – Orchid Cellmark has licensed part of its diagnostic and forensics intellectual property portfolio to Illumina in exchange in for an upfront fee, potential milestone payments, and royalties.
The license for Orchid's single base nucleotide extension technology includes an $850,000 license fee, a potential $150,000 in milestone payments, and royalties from Illumina through any subcontracting agreements. Orchid also will be able to buy certain Illumina products utilizing the patents as a preferred customer.
Orchid retains the rights to use the licensed patents in all fields of use.
"This transaction allows Orchid to work with Illumina to further strengthen our long term competitive position in providing DNA forensic testing services," Thomas Bologna, Orchid Cellmark's president and CEO, said in a statement.